B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates.
A transfusional B19 parvovirus infection may have severe consequences in immunocompromised hosts. The presence of B19 DNA was investigated with a polymerase chain reaction (PCR) assay in 30 batches of solvent/detergent-treated clotting factor concentrates (12 batches of factor VIII, 16 batches of factor IX, 1 batch of factor VII, and 1 batch of PPSB). B19 DNA was detected in 6 (20%) batches, including 3 factor VIII and 3 factor IX concentrates. Because of the frequency of B19 DNA in batches of clotting factors, measures to prevent transfusional risk of B19 infection via these blood products are justified, especially in recipients immunocompromised by HIV infection.
Lefrère
J J
JJ
Institut National de Transfusion Sanguine, Hôpital Saint-Antoine, Paris, France.
Mariotti
M
M
Thauvin
M
M
D001779:Blood Coagulation Factors; D016913:Blood Component Transfusion / Q000009:adverse effects*; D001782:Blood Donors; D015897:Comorbidity; D004279:DNA, Viral / Q000032:analysis*; D003902:Detergents; D016731:Erythema Infectiosum / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control / Q000635:transmission*; D005069:Evaluation Studies as Topic; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology; D006467:Hemophilia A / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D017053:Infection Control / Q000379:methods*; D008403:Mass Screening; D016732:Parvovirus B19, Human; D016133:Polymerase Chain Reaction / Q000379:methods; D012307:Risk Factors; D012997:Solvents; D014021:Tissue Preservation
D001779:Blood Coagulation Factors; D004279:DNA, Viral; D003902:Detergents; D012997:Solvents